Vaxcyte Hits 52-Week High as Phase 3 Data Boosts VAX-31 Prospects
Vaxcyte reached a new 52-week high after positive topline Phase 3 OPUS-1 results strengthened the case for its VAX-31 vaccine.
Alvotech Shares Jump 13.5% After FDA Clears AVT02 Manufacturing Changes
Alvotech’s $ALVO shares jumped 13.5% after FDA approval of AVT02 manufacturing changes, sharpening the focus on supply and commercial scale-up.
Trade with the conviction of the 1%.
Institutional-grade market intelligence delivered before the opening bell.
Cenovus’s $5.7 Billion Athabasca Deal Reshapes Canadian Oil Sands Landscape
Cenovus’s $5.7 billion cash-and-stock Athabasca acquisition could accelerate oil sands consolidation and reshape investo…
Harrow Expands Ophthalmology Franchise With Completed TYRVAYA Acquisition
Harrow completed its TYRVAYA acquisition, adding the first and only FDA-approved nasal spray for dry eye disease to its …
GE HealthCare’s $945 Million Sofie Deal Signals Broader Radiopharmaceutical Push
GE HealthCare’s $945 million Sofie Biosciences acquisition could deepen its precision-imaging strategy while putting int…
Qiagen Shares Gain as Strategic-Buyer Talks Raise M&A Speculation
Qiagen shares gained after a report said talks with a strategic buyer had advanced, reviving questions about consolidati…
Pancreatic Cancer Drug Approval Could Lift Oncology Biotech Sentiment
An FDA approval for metastatic pancreatic cancer may improve sentiment across oncology biotech, though investors still l…
AbbVie’s JUVMO Approval Opens New Parkinson’s Growth Opportunity for Investors
AbbVie’s FDA approval of JUVMO may expand its neurology pipeline and offer a potential diversification catalyst beyond i…
Spyre Therapeutics Insiders Sell More Than $3.6 Million in SYRE Stock Despite Bullish Analyst Coverage
Spyre insiders sold more than $3.6 million in SYRE stock as JPMorgan and Baird maintained bullish views, sharpening the …
MRNA’s Nasdaq-100 Inclusion Draws Retail Attention to SLS and IBRX
Moderna’s Nasdaq-100 inclusion may increase index-related attention, while retail traders compare smaller biotech names …
AbbVie Wins FDA Approval for JUVMO Parkinson’s Therapy: What ABBV Investors Should Watch
AbbVie’s FDA approval of JUVMO adds a Parkinson’s therapy to its neuroscience portfolio, but commercial execution remain…